Regenerative Approach for COPD
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Advanced regenerative treatment to improve lung function, reduce inflammation, and enhance quality of life for COPD patients.
Can stem cell therapy help COPD?
Mesenchymal stem cell therapy is not an approved treatment for COPD. Trials to date report that administration is generally well tolerated and can reduce some inflammatory markers, but they have not shown consistent improvement in lung function or exacerbation rates. Smoking cessation, inhaled therapy and pulmonary rehabilitation remain the interventions with proven benefit.
Key facts
- Approval status
- Not approved for COPD
- Trial findings
- Well tolerated; lung-function benefit not demonstrated
- Proven care
- Cessation, inhalers, pulmonary rehabilitation
What we know
- Randomised MSC studies in COPD have reported safety and reductions in some inflammatory markers.
What remains uncertain
- Whether any measurable change in FEV1 or exacerbation frequency follows treatment.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — COPD
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — early-stage only
- Randomised trials?
- A small number of randomised trials; no confirmed effect on lung function
- Main outcomes studied
- FEV1 and lung function
- 6-minute walk
- Exacerbation rate
- Inflammatory markers
- Safety
- Long-term evidence
- Very limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — COPD — PubMed
- Randomised controlled trials — COPD — PubMed
- Registered MSC trials — COPD — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What is COPD and How Can Stem Cells Help?
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition that makes breathing difficult. It includes emphysema and chronic bronchitis, characterized by airflow limitation and chronic inflammation of the airways.
Traditional treatments focus on symptom management through bronchodilators, corticosteroids, and oxygen therapy. While these can help, they don't address the underlying lung damage. Regenerative medicine approach offers a regenerative approach.
Mesenchymal stem cells (MSCs) from umbilical cord tissue have powerful anti-inflammatory and regenerative properties. They can help reduce lung inflammation, promote tissue repair, and potentially slow disease progression.
Benefits for COPD Patients
Discover how regenerative medicine can help improve your lung function and quality of life.
Improved Lung Function
Many patients experience improvements in breathing capacity and pulmonary function tests.
Reduced Inflammation
MSCs have powerful anti-inflammatory properties that help calm chronic lung inflammation.
Tissue Regeneration
Stem cells promote repair of damaged lung tissue and support natural healing processes.
Enhanced Quality of Life
Improved breathing often leads to better sleep, more energy, and increased activity levels.
Slowed Disease Progression
Treatment may help slow the progression of lung damage and decline in function.
Reduced Symptoms
Many patients report less coughing, wheezing, and shortness of breath after treatment.
How Stem Cells Work for COPD
Mesenchymal regenerative medicine approach for chronic obstructive pulmonary disease (COPD) targets the progressive lung tissue destruction and chronic inflammation that characterize this condition. Clinical studies suggest MSCs can reduce pulmonary inflammation, promote alveolar repair, and improve respiratory function.
MSCs deliver potent anti-inflammatory effects to the lungs by secreting cytokines that suppress the chronic pulmonary inflammation driving COPD progression. This includes reduction of neutrophilic inflammation, oxidative stress, and protease-antiprotease imbalance in the airways.
Stem cells promote the regeneration of damaged alveolar epithelial cells by stimulating type II pneumocyte proliferation and differentiation. Clinical studies suggest this alveolar repair can improve gas exchange efficiency and gradually enhance oxygen saturation levels.
MSC therapy modulates the pulmonary immune response by reducing the excessive macrophage activation and T-cell mediated damage in the lungs. This immunomodulation helps slow the progressive tissue destruction that leads to emphysematous changes.
Research indicates that MSCs secrete hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) that promote bronchial epithelial repair and reduce airway fibrosis. These trophic effects help improve airway caliber and reduce the air trapping characteristic of COPD.
Who Is a Good Candidate?
Candidacy for regenerative medicine approach in COPD is assessed through pulmonary function testing, imaging studies, and comprehensive respiratory evaluation. Our pulmonary specialists determine which patients are most likely to benefit from regenerative lung therapy.
Ideal Candidates
- Patients with moderate to severe COPD (GOLD stages II-III) confirmed by spirometry
- Individuals experiencing progressive decline in lung function despite optimal medical management
- Patients with COPD-related limitations in daily activities and exercise tolerance
- Former smokers who have quit smoking and wish to support lung recovery
- Those seeking complementary approaches to enhance the effectiveness of standard COPD treatments
May Not Be Suitable
- Patients who continue to actively smoke tobacco products
- Individuals with end-stage COPD requiring continuous mechanical ventilation
- Patients with active pulmonary infections or untreated tuberculosis
- Those with active lung malignancies or undiagnosed pulmonary nodules
What Results Can You Expect?
Improvements in COPD following regenerative medicine approach develop gradually as lung tissue repair and anti-inflammatory effects take hold. Results vary based on disease severity, duration of COPD, smoking history, and overall respiratory health.
Initial Recovery
Minimal recovery is needed following intravenous administration. Some patients may experience temporary mild respiratory irritation. Continuation of all prescribed COPD medications and oxygen therapy is essential.
Early Improvements
Gradual reduction in pulmonary inflammation. Many patients report decreased frequency and severity of breathlessness episodes. Some notice improved energy levels and reduced coughing.
Progressive Results
Continued improvement in exercise tolerance and daily activity capacity. Patients often report reduced reliance on rescue inhalers and improved ability to walk longer distances without significant breathlessness.
Optimal Results
Peak therapeutic benefits with measurable improvements in pulmonary function tests. Enhanced quality of life with greater independence in daily activities. Reduction in COPD exacerbation frequency is commonly observed.
Long-Term Benefits
Sustained respiratory improvements with ongoing lung tissue repair. Follow-up spirometry may show stabilized or improved lung function values. Periodic reassessment helps determine if additional treatments would be beneficial.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"My hepatologist said the liver scan improvement was remarkable. I was preparing for the worst — now I'm planning for the future."
"I flew to Istanbul sceptical. Six months later, my endocrinologist at home took me off insulin. The numbers speak for themselves."
Care Process
Our comprehensive approach ensures you receive personalized care at every step of your approach journey.
Pulmonary Evaluation
Complete respiratory assessment including pulmonary function tests and imaging.
Specialist Consultation
Meet with our pulmonology team to discuss your condition and treatment options.
Cell Preparation
High-quality MSCs are prepared in our GMP-certified laboratory facilities.
Treatment Administration
Stem cells are administered via IV infusion or nebulization as appropriate.
Follow-Up Care
Regular monitoring and follow-up appointments to track your respiratory progress.
Frequently Asked Questions
Get answers to common questions about regenerative medicine approach for COPD.
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Treatments
Cardiovascular Disease
Learn about candidacy, delivery, evidence, and follow-up for Cardiovascular Disease.
Learn MoreAngina
Learn about candidacy, delivery, evidence, and follow-up for Angina.
Learn MoreIschemic Cardiomyopathy
Learn about candidacy, delivery, evidence, and follow-up for Ischemic Cardiomyopathy.
Learn MoreRelated Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Regenerative Medicine for Liver Disease: Support & Progress
How mesenchymal stem cell approaches may support liver health in cases of cirrhosis, fatty liver, and fibrosis, promoting tissue support and hepatic function.
Read ArticleManaging Diabetes with Regenerative Medicine
Explore the role of regenerative medicine in diabetes management, including potential benefits for insulin production and blood sugar regulation through cellular regeneration.
Read ArticleUnderstanding Regenerative Medicine: A Complete Guide
A comprehensive overview of stem cell therapy, including types of stem cells, care processes, safety considerations, and what patients can expect during their wellness journey.
Read ArticleHow Much Does This Cost Worldwide?
Compare this regenerative medicine costs at StemCell Longevita versus clinics in other countries.
| Country | Typical Cost |
|---|---|
| United States | $15,000 – $30,000 |
| United Kingdom | £12,000 – £25,000 |
| Germany | €15,000 – €30,000 |
| South Korea | $12,000 – $25,000 |
| StemCell Longevita (Turkey) | From £7,600 |
Prices based on market research of comparable stem cell clinics offering umbilical cord-derived MSC treatments (2025-2026). Actual prices vary by clinic, cell count, and condition.
Related clinical questions
Where this page sits in the wider picture.